Published in Proc Natl Acad Sci U S A on April 16, 1996
Real time detection of DNA.RNA hybridization in living cells. Proc Natl Acad Sci U S A (1998) 3.10
Shal-type channels contribute to the Ca2+-independent transient outward K+ current in rat ventricle. J Physiol (1997) 1.65
Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target. Proc Natl Acad Sci U S A (1997) 1.49
Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc Natl Acad Sci U S A (1998) 1.21
Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide. Antimicrob Agents Chemother (1999) 0.87
Glycotargeting to improve cellular delivery efficiency of nucleic acids. Glycoconj J (2007) 0.79
The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Biol Proced Online (2004) 0.78
A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells. J Cancer Res Clin Oncol (2003) 0.76
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem (1994) 6.04
Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science (1991) 5.40
Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation. Science (1989) 3.88
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 3.42
Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci U S A (1991) 3.14
A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science (1988) 2.88
Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science (1996) 2.63
Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol (1995) 2.05
G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science (1989) 1.96
The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Des (1991) 1.81
In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.67
Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des (1993) 1.61
In vivo transcription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide. Nucleic Acids Res (1993) 1.46
Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest (1995) 1.44
Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood (1993) 1.42
DNA complexes with polycations for the delivery of genetic material into cells. Bioconjug Chem (1995) 1.40
Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem (1992) 1.36
Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A (1995) 1.21
Homologous recombination for gene replacement in mouse cell lines. Methods Cell Biol (1994) 1.17
Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol (1993) 1.16
Gene targeting in the mouse. Bioessays (1994) 1.16
Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.14
Effect of competing self-structure on triplex formation with purine-rich oligodeoxynucleotides containing GA repeats. Nucleic Acids Res (1995) 1.14
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 1.10
Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci U S A (1992) 1.09
Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A (1994) 1.04
Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur J Cancer (1991) 1.03
Transferrinfection: a highly efficient way to express gene constructs in eukaryotic cells. Ann N Y Acad Sci (1992) 0.89
Blood. Thrombopoietin--at last. Nature (1994) 0.82
Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells. Blood (1995) 0.81
RNA structure. Describing the elephant. Curr Biol (1995) 0.77
Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A (1989) 3.27
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol (1999) 2.79
Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science (1996) 2.63
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther (2002) 2.52
Genetic instability induced by the tumor microenvironment. Cancer Res (1996) 2.33
Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood (2008) 2.32
Detection and analysis of UV-induced mutations in mammalian cell DNA using a lambda phage shuttle vector. Proc Natl Acad Sci U S A (1986) 2.30
Pulmonary tumor embolism: a review of the literature. Am J Med (2003) 2.23
Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med (1997) 2.12
Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol (1995) 2.05
Specific mutations induced by triplex-forming oligonucleotides in mice. Science (2000) 1.98
Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res (1989) 1.98
Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem (1995) 1.78
Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res (1997) 1.76
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry (1989) 1.70
Targeted mutagenesis of DNA using triple helix-forming oligonucleotides linked to psoralen. Proc Natl Acad Sci U S A (1993) 1.69
Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene (2006) 1.68
Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene (2003) 1.58
Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res (1990) 1.57
Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol (2001) 1.55
Triplex DNA: fundamentals, advances, and potential applications for gene therapy. J Mol Med (Berl) (1997) 1.54
A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci U S A (2001) 1.52
Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc Natl Acad Sci U S A (1997) 1.51
Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat Genet (1998) 1.51
Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res (1998) 1.44
ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A (2001) 1.42
Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide. J Virol (1993) 1.40
Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway. Mol Cell Biol (2000) 1.40
Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res (1999) 1.38
Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res (2000) 1.37
Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A (1995) 1.36
p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res (1995) 1.36
Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant. Proc Natl Acad Sci U S A (1996) 1.34
Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet (2001) 1.34
Different mutator phenotypes in Mlh1- versus Pms2-deficient mice. Proc Natl Acad Sci U S A (1999) 1.32
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res (2000) 1.30
Mutagenesis induced by the tumor microenvironment. Mutat Res (1998) 1.29
Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A (1997) 1.27
Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev (1994) 1.27
Recombination induced by triple-helix-targeted DNA damage in mammalian cells. Mol Cell Biol (1996) 1.27
Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide. J Biol Chem (1999) 1.27
Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev (1995) 1.26
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). Gene (1988) 1.26
Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine. Proc Natl Acad Sci U S A (1992) 1.24
Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res (1994) 1.23
Altered repair of targeted psoralen photoadducts in the context of an oligonucleotide-mediated triple helix. J Biol Chem (1995) 1.22
Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc Natl Acad Sci U S A (1998) 1.21
Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. J Biol Chem (2001) 1.21
Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences. Nat Biotechnol (2000) 1.19
DNA mismatch repair detected in human cell extracts. Mol Cell Biol (1987) 1.17
Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A (1993) 1.17
Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrob Agents Chemother (1990) 1.16
Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin Cancer Res (1999) 1.15
Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase. J Biol Chem (1989) 1.13
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci U S A (2006) 1.13
The Tyr-265-to-Cys mutator mutant of DNA polymerase beta induces a mutator phenotype in mouse LN12 cells. Proc Natl Acad Sci U S A (1999) 1.11
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.11
Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res (1997) 1.09
Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation. Nucleic Acids Res (1994) 1.09
Oligodeoxynucleotides interact with recombinant CD4 at multiple sites. J Biol Chem (1993) 1.08
Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer (1999) 1.08
High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells. Proc Natl Acad Sci U S A (2000) 1.07
Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways. Cancer Res (2000) 1.07
High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage lambda DNA using a new E.coli lysogen. Nucleic Acids Res (1993) 1.05
Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin Cancer Res (2006) 1.04
Triplex formation by oligonucleotides containing 5-(1-propynyl)-2'-deoxyuridine: decreased magnesium dependence and improved intracellular gene targeting. Biochemistry (1999) 1.04
Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. J Biol Chem (2001) 1.03
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol Cancer Ther (2005) 1.02
Phosphorothioate oligonucleotides block the VDAC channel. Biophys J (2007) 1.01
Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res (1997) 1.01
Suramin: prototype of a new generation of antitumor compounds. Cancer Cells (1990) 1.00
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides (2006) 0.99
Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine. Nucleic Acids Res (1997) 0.99
Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm (2002) 0.99
Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm (2000) 0.99
Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. Nucleic Acids Res (1999) 0.98
Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A (1994) 0.96
Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. Proc Natl Acad Sci U S A (1987) 0.96
Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol Biol (2012) 0.96
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res (2004) 0.95
Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res (1995) 0.94
Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by offoadducts as well as cross-links. Cancer Res (1995) 0.94
Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem (1991) 0.94
Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther (2006) 0.93
Frequent spontaneous deletions at a shuttle vector locus in transgenic mice. Mutagenesis (1996) 0.92
Gallbladder distention in ill preterm infants. Am J Dis Child (1983) 0.92
Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood (1988) 0.92
Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides (2006) 0.92
Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res (1996) 0.91
Gene targeting via triple-helix formation. Prog Nucleic Acid Res Mol Biol (2001) 0.91
Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity. Clin Cancer Res (1995) 0.91
Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res (2002) 0.91
Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. Carcinogenesis (2000) 0.90
Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice. Cancer Res (2001) 0.89
Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Ther (2012) 0.87
Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst (1989) 0.87
Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Clin Cancer Res (1997) 0.86